Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)

NCT03020992 is registered in ClinicalTrials.gov with UCB Biopharma SRL as lead sponsor.

NCT NCT03020992
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03020992 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Open-Label Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis Flares in Axial Spondyloarthritis Subjects With a History of Anterior Uveitis (C-VIEW)
Lead sponsor
UCB Biopharma SRL
Phase
Phase 4
Overall status
Completed
Start date
December 21, 2016
Completion date
January 23, 2020
Enrollment
89 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

anterior uveitis (au), axial spondyloarthritis (axspa)